JOURNAL ARTICLE
Add like
Add dislike
Add to saved papers

[Calciphylaxis].

Calciphylaxis is a form of extra-skeletal calcification characterized by calcium deposits in arterial tunica media and vascular thrombosis, which leads to tissue ischemia including skin ischemia with consequential skin necrosis. Necroses may also develop in the subcutaneous adipose tissue and skeletal muscle. The cause of this disorder remains unknown. It was first described by Bryant and White as early as 1989 in association with uremia, and the syndrome remained clinically inadequately recognizable until 1976. Then, Gipstein and coworkers described the disorder in more detail, followed by a great number of calciphylaxis case reports since then, including data on morbidity and therapeutic dilemmas. Calciphylaxis has been reported in association with hepatic insufficiency, obesity, and diabetes mellitus. The authors present the clinical procedure of identifying and treating major ulcerations on both lower legs in a patient with polymorbidity and recognized calciphylaxis, which caused skin necroses with consequential chronic leg ulcers.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app